Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (4,547)

Search Parameters:
Keywords = registry

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
14 pages, 964 KiB  
Review
Optic Pathway Glioma: Current Treatment Approaches and Ongoing Clinical Trials
by Osama Elzaafarany, Sarah Elhomosany, Alexandra Rincones, Vincent Dlugi and Sepideh Mokhtari
Brain Sci. 2025, 15(8), 894; https://doi.org/10.3390/brainsci15080894 (registering DOI) - 21 Aug 2025
Abstract
Optic pathway glioma (OPG) is a rare pediatric low-grade glioma, frequently associated with neurofibromatosis type 1 (NF–1), that presents unique therapeutic challenges due to its anatomical location and its potential to impair vision, endocrine function, and developmental trajectories. Current clinical management prioritizes a [...] Read more.
Optic pathway glioma (OPG) is a rare pediatric low-grade glioma, frequently associated with neurofibromatosis type 1 (NF–1), that presents unique therapeutic challenges due to its anatomical location and its potential to impair vision, endocrine function, and developmental trajectories. Current clinical management prioritizes a multidisciplinary, patient-specific approach aimed at tumor control while preserving long-term quality of life. Strategies vary based on clinical presentation, ranging from observation in asymptomatic cases to chemotherapy for progressive or symptomatic tumors. Surgical and radiation options are limited due to potential risks and complications. In recent years, advances in molecular characterization have guided the development of targeted therapies, particularly MEK inhibitors, which demonstrate encouraging efficacy and reduced toxicity profiles. In parallel, investigational therapies including immunotherapy and precision medicine-based approaches are under clinical evaluation. This review provides a synthesis of current standard practices, emerging targeted treatments, and ongoing clinical trials, drawing on relevant literature and expert consensus to inform clinicians and families about available therapeutic options. Literature discussed in this review was identified through a non-systematic search of published articles, clinical trial registries, and authoritative guidelines, with selection based on relevance, clinical significance, and contribution to understanding current and emerging management strategies for OPG. Full article
(This article belongs to the Section Neuroglia)
Show Figures

Figure 1

12 pages, 592 KiB  
Article
High-Quality Targeted Temperature Management After Cardiac Arrest; Results from the Korean Hypothermia Network Prospective Registry
by Hyo Jin Bang, Chun Song Youn, Byung Kook Lee, Sang Hoon Oh, Hyo Joon Kim, Ae Kyung Gong, Ji-Sook Lee, Soo Hyun Kim, Kyu Nam Park, In Soo Cho and on behalf of the Korean Hypothermia Network Investigators
J. Clin. Med. 2025, 14(16), 5898; https://doi.org/10.3390/jcm14165898 - 21 Aug 2025
Abstract
Backgrounds: Most out-of-hospital cardiac arrest (OHCA) survivors are comatose due to hypoxic ischemic brain injury. Targeted temperature management (TTM) is the only evidence-based neuroprotective intervention for this condition; however, the optimal implementation of TTM has yet to be determined. The concept of high-quality [...] Read more.
Backgrounds: Most out-of-hospital cardiac arrest (OHCA) survivors are comatose due to hypoxic ischemic brain injury. Targeted temperature management (TTM) is the only evidence-based neuroprotective intervention for this condition; however, the optimal implementation of TTM has yet to be determined. The concept of high-quality TTM has been proposed to improve patient outcomes, but its clinical impact has not been thoroughly evaluated. This study investigates whether adherence to high-quality TTM is associated with improved neurological outcomes and survival among OHCA patients. Methods: This retrospective analysis used data from the Korean Hypothermia Network Prospective Registry 1.0, including 1060 adult OHCA patients treated with TTM at 33 °C between 2015 and 2018. High-quality TTM was defined as follows: temperature variability during maintenance within ±1.0 °C, maintenance duration ≥ 24 h, rewarming rate ≤ 0.5 °C/h, and post-TTM fever control (temperature < 38.5 °C). Patients were classified into high- and low-quality TTM groups. The primary outcomes were survival and neurological status (CPC ranging from 1 to 2 indicated a good outcome) 6 months after cardiac arrest (CA). Results: Of the 1060 patients, 491 (46.3%) received high-quality TTM. Compared with the low-quality TTM group, the high-quality TTM group had higher rates of survival (44.6% vs. 36.4%, p = 0.006). Multivariate analysis revealed that high-quality TTM was independently associated with survival (OR 1.802, 95% CI: 1.171–2.773) and good neurological outcomes (OR 1.748, 95% CI: 1.102–2.770). Conclusions: High-quality TTM is associated with improved survival and better neurological outcomes in OHCA patients. Standardizing TTM delivery on the basis of quality metrics may increase its effectiveness in clinical practice. Full article
(This article belongs to the Section Emergency Medicine)
Show Figures

Figure 1

20 pages, 1094 KiB  
Article
Aims and Rationale of a National Registry Integrating Clinical, Echocardiographic, and Multi-Omics Profiling to Promote Precision Medicine in Peripartum Cardiomyopathy
by Alessia Palmentieri, Ciro Battaglia, Dario D’Alconzo, Luigi Anastasia, Luca Bardi, Giuseppe Bifulco, Maria Calanducci, Martina Carotenuto, Paolo Ivo Cavoretto, Federica Carusone, Emilio Di Lorenzo, MariaFrancesca Di Santo, Attilio Di Spiezio Sardo, Federica Ilardi, Danila Ioele, Francesca Lanni, Marco Licciardi, Francesco Loffredo, Rachele Manzo, Daniele Masarone, Nicolò Montali, Roberta Paolillo, Vanessa Peano, Giovanni Peretto, Enrica Pezzullo, Pina Polese, Gabriele Saccone, Alaide Chieffo, Giovanni Esposito and Cinzia Perrinoadd Show full author list remove Hide full author list
Biomedicines 2025, 13(8), 2026; https://doi.org/10.3390/biomedicines13082026 - 20 Aug 2025
Abstract
Background. Peripartum cardiomyopathy (PPCM) is a rare but potentially life-threatening condition typically presenting as heart failure with reduced ejection fraction in the last month of pregnancy or in the first five months following delivery in women without other known causes of heart failure. [...] Read more.
Background. Peripartum cardiomyopathy (PPCM) is a rare but potentially life-threatening condition typically presenting as heart failure with reduced ejection fraction in the last month of pregnancy or in the first five months following delivery in women without other known causes of heart failure. PPCM incidence and prevalence are highly variable in different populations and geographical areas. The etiology of PPCM is likely multifactorial, with genetic predisposition, autoimmune conditions, nutritional deficiencies, hormonal and metabolic changes, myocardial inflammation, enhanced oxidative stress, vascular dysfunction, and angiogenic imbalance all listed as possible contributing factors. Objectives. The complexity and multifactorial nature of PPCM can be explored by large-scale “omics” investigations, and their integration has the potential to identify key drivers and pathways that have the largest contribution to the disease. The scarcity of relevant knowledge and experience with most rare diseases raises the unique need for cooperation and networking. Methods and results. In the context of PPCM, we hypothesize that the creation of prospective patient registries could represent an answer to this criticality. Therefore, we created a multicenter national registry of PPCM in different geographical areas in Italy. Conclusions. We expect that the integration of clinical, imaging and omics-based data might provide novel insights into PPCM pathophysiology and allow in the future early detection, risk assessment, and patient-specific therapeutic interventions, thereby offering new perspectives in precision medicine. Full article
(This article belongs to the Special Issue Heart Failure: New Diagnostic and Therapeutic Approaches)
Show Figures

Graphical abstract

16 pages, 589 KiB  
Article
The Cervical Lymph Node Positive Metastatic Probability Is a Significant Predictor of Survival for Oral Squamous Cell Carcinoma—A Nationwide Study
by Li-Jen Liao, Cheng-Lin Lu, Yu-Ping Cheng, Ping-Chia Cheng, Yong-Chen Chen, Chun-Ju Chiang, Wen-Chung Lee, San-Lin You and Wan-Lun Hsu
Cancers 2025, 17(16), 2704; https://doi.org/10.3390/cancers17162704 - 20 Aug 2025
Abstract
Background/Objectives: This study aimed to evaluate the prognostic significance of lymph node density (LND) and the log odds of positive lymph nodes (LODDS) in patients with oral squamous cell carcinoma (OSCC) using a nationwide database. Methods: A retrospective cohort study was conducted using [...] Read more.
Background/Objectives: This study aimed to evaluate the prognostic significance of lymph node density (LND) and the log odds of positive lymph nodes (LODDS) in patients with oral squamous cell carcinoma (OSCC) using a nationwide database. Methods: A retrospective cohort study was conducted using the Taiwan Cancer Registry to identify patients diagnosed with OSCC who underwent surgery for both the primary tumor and neck dissection. Clinicopathological variables were collected, and survival outcomes were analyzed using Cox proportional hazards models. LND was categorized as negative, <0.05, and ≥0.05; LODDS was grouped into four categories: <−4, −4 to −3.5, −3.5 to −2.5, and ≥−2.5. Results: A total of 1643 female and 15,475 male patients were included, with a mean age of 57.4 years (range, 20–98 years). In multivariable Cox regression analyses, LND and LODDS were identified as independent prognostic factors for overall survival. Compared with patients with negative LND, the hazard ratios for LND < 0.05 and LND ≥0.05 were 2.12 (95% CI, 1.90–2.36) and 3.35 (95% CI, 3.05–3.67), respectively (p < 0.01). Similarly, relative to the lowest LODDS group (<−4), the hazard ratios for the higher categories were 1.51 (95% CI, 1.32–1.74) for −4 to −3.5, 2.30 (95% CI, 2.05–2.57) for −3.5 to −2.5, and 4.32 (95% CI, 3.85–4.86) for ≥−2.5 (p < 0.01). Conclusions: LND and LODDS are significant prognostic indicators in OSCC. Incorporating these lymph node–based metrics into prognostic models may enhance risk stratification and inform clinical decision-making. Full article
(This article belongs to the Section Cancer Survivorship and Quality of Life)
Show Figures

Figure 1

11 pages, 357 KiB  
Article
Impact of COVID-19 on the Stage and Treatment of Endometrial Cancer: A Cancer Registry Analysis from an Italian Comprehensive Cancer Center
by Francesca Roncaglia, Lucia Mangone, Francesco Marinelli, Isabella Bisceglia, Maria Barbara Braghiroli, Valentina Mastrofilippo, Fortunato Morabito, Antonia Magnani, Antonino Neri, Lorenzo Aguzzoli and Vincenzo Dario Mandato
Cancers 2025, 17(16), 2686; https://doi.org/10.3390/cancers17162686 - 18 Aug 2025
Viewed by 85
Abstract
Background/Objectives: The COVID-19 pandemic has impacted cancer diagnosis and treatment. This study assessed the effects of the pandemic on the stage and delays between diagnosis and treatment in endometrial cancer. Methods: The study included 543 cases diagnosed between 2017 and 2023 [...] Read more.
Background/Objectives: The COVID-19 pandemic has impacted cancer diagnosis and treatment. This study assessed the effects of the pandemic on the stage and delays between diagnosis and treatment in endometrial cancer. Methods: The study included 543 cases diagnosed between 2017 and 2023 in a population-based cancer registry. Data on stage, diagnostic procedures, treatments, and time to surgery (TTS) were compared across the pre-COVID (2017—2019), COVID (2020—2022), and post-COVID (2023) periods. Multiple regression analysis was used to identify factors influencing TTS. Results: During the three periods, stages I and II showed no variation, whereas a significant increase was recorded in stage III (7.5%, 9.5%, and 17.8%, respectively; p < 0.05), as well as a slight increase in grade 3 (15.4%, 13.6%, and 19.2%, respectively). A significant decrease in laparotomies (30.3%, 11.6%, and 11.0%, respectively; p < 0.01) and an increase in laparoscopies (60.1%, 78.1%, and 80.8%, respectively; p < 0.05) were observed. TTS decreased for interventions performed within 30 days (10.1%, 3.7%, and 1.4%, respectively; p < 0.01) and within 60 days (38.6%, 19.4%, and 6.9%, respectively; p < 0.01), while a significant increase was observed for >60 days (22.8%, 29.8%, and 37.0%, respectively; p < 0.05) and >90 days (7.5%, 23.1%, and 20.5%, respectively; p < 0.01). Multivariable analysis confirmed a reduction in TTS in the pre-COVID period (β −19.63; CI 95% −31.31; −7.95) and an increase in the post-COVID period (β 31.60; CI 95% 13.68; 49.53); while an increase was confirmed only for stage IV (β 48.80; CI 95% 23.15; 74.45). Conclusions: The COVID-19 pandemic has led to an increase in more advanced cancers and delays in surgery. Full article
Show Figures

Figure 1

13 pages, 1704 KiB  
Article
Socioeconomic Disparities and Risk of Papillary Thyroid Cancer Associated with Environmental Exposure to Per- and Polyfluoroalkyl Substances (PFAS) in Florida
by Laura E. Wild, Nicholas DiStefano, Garrett Forman, Bianca I. Arocha, Ming S. Lee, Peter A. Borowsky, Elizabeth Franzmann, Natasha Solle, Alberto J. Caban-Martinez and Erin Kobetz
Int. J. Environ. Res. Public Health 2025, 22(8), 1290; https://doi.org/10.3390/ijerph22081290 - 18 Aug 2025
Viewed by 76
Abstract
The existing literature suggests that exposure to Per- and Polyfluoroalkyl Substances (PFAS) can increase Papillary Thyroid Cancer (PTC) risk by interfering with thyroid hormone signaling, leading to hormonal imbalances that promote carcinogenesis. In addition, significant disparities exist in environmental exposure. However, ecological evidence [...] Read more.
The existing literature suggests that exposure to Per- and Polyfluoroalkyl Substances (PFAS) can increase Papillary Thyroid Cancer (PTC) risk by interfering with thyroid hormone signaling, leading to hormonal imbalances that promote carcinogenesis. In addition, significant disparities exist in environmental exposure. However, ecological evidence of these associations has not been established within a statewide database of cancer outcomes. Therefore, this study investigated the relationship between socioeconomic conditions, environmental PFAS exposure, and PTC incidence in Florida using the state’s cancer registry. Data on facilities potentially releasing PFAS and ZIP codes with known PFAS drinking water contamination were retrieved from the EPA’s PFAS Analytic Tool. Proximity to PFAS sites and age-adjusted incidence by patient race/ethnicity were calculated by census tract. Lower socioeconomic status was associated with greater exposure to environmental PFAS. Census tracts with closer proximity to PFAS sites were more likely to have public water systems with PFAS contamination. Lastly, residential proximity to PFAS sites was positively associated with age-adjusted PTC incidence in Non-Hispanic Whites and Hispanics. These results demonstrate disparities in environmental exposure and suggest that exposure to PFAS may be an important factor for PTC risk at the population level and should be considered in the development of public health policies. Full article
(This article belongs to the Special Issue Environmental Epidemiology and Spatial Analysis)
Show Figures

Figure 1

12 pages, 254 KiB  
Article
Healthcare Costs by Comorbidity Patterns in Lung Cancer Patients
by Alessandra Buja, Massimo Rugge, Marcello Di Pumpo, Manuel Zorzi, Federico Rea, Ilaria Pantaleo, Giovanna Scroccaro, Pierfranco Conte, Leonardo Rigon, Giorgio Arcara, Giulia Pasello and Valentina Guarneri
Cancers 2025, 17(16), 2682; https://doi.org/10.3390/cancers17162682 - 18 Aug 2025
Viewed by 71
Abstract
Introduction: Lung cancer imposes a substantial economic burden on patients, healthcare systems, and societies due to its high prevalence and costs associated with diagnosis, treatment, and palliative care. Comorbidities in lung cancer patients can further complicate clinical management and increase healthcare utilization. This [...] Read more.
Introduction: Lung cancer imposes a substantial economic burden on patients, healthcare systems, and societies due to its high prevalence and costs associated with diagnosis, treatment, and palliative care. Comorbidities in lung cancer patients can further complicate clinical management and increase healthcare utilization. This study investigated the impact of comorbidity patterns on healthcare costs in patients with lung cancer. Methods: A cohort of 1540 lung cancer patients in the Veneto region of Italy was divided into five groups based on comorbidity burden using latent class analysis: no comorbidities, only one comorbidity, and specific comorbidity classes (Class 1: cardiovascular, respiratory, and endocrine diseases; Class 2: multiorgan diseases; Class 3: socio-multifactorial neuro conditions). Using administrative data, both overall healthcare costs and lung cancer-specific costs were analyzed over three years. Results: Patients with one comorbidity class had the highest overall costs over three years from diagnosis (USD 52,039) and the highest lung-specific costs (USD 47,804). In contrast, patients in the Cardiovascular-Respiratory and Endocrine class incurred the lowest overall costs (USD 38,447). Additionally, they had the lowest lung case-specific costs (USD 33,425) over the same three-year period from diagnosis. Higher costs for inpatient medications were observed in patients without any comorbidities or with at most one. Conclusions: The findings emphasize the significant effect of comorbidity patterns on resource use in lung cancer patients. Considering comorbidity profiles is essential for economic assessments and healthcare planning, as it allows for better resource allocation and supports personalized treatment strategies. Full article
14 pages, 757 KiB  
Article
OCT for Optimizing Long-Term Clinical Results in Left Main PCI—Dream or Reality? Results from a Single-Center High-Volume Registry
by Florin-Leontin Lazar, Teodor Paul Kacso, Calin Homorodean, Mihai Ober, Horea-Laurentiu Onea, Dan Tataru, Mihai Spinu, Maria Olinic, Minodora Teodoru and Dan-Mircea Olinic
J. Clin. Med. 2025, 14(16), 5824; https://doi.org/10.3390/jcm14165824 - 18 Aug 2025
Viewed by 138
Abstract
Background: With growing evidence regarding long-term clinical results of left main angioplasty, it has become clear that the gap between percutaneous coronary interventions (PCIs) and bypass surgery can be narrowed only by improving the PCI technique. While intravascular ultrasound (IVUS) has become routinely [...] Read more.
Background: With growing evidence regarding long-term clinical results of left main angioplasty, it has become clear that the gap between percutaneous coronary interventions (PCIs) and bypass surgery can be narrowed only by improving the PCI technique. While intravascular ultrasound (IVUS) has become routinely used for this subset of lesions, there is still insufficient data regarding the role of optical coherence tomography (OCT) in left main PCI. Aims: The aim of this study was to investigate the long-term results of OCT-guided PCI in comparison to angiographical guidance alone. Material and methods: We conducted a retrospective single-center high-volume analysis of patients with left main disease treated by PCI. The primary endpoint was all-cause death. Results and discussion: Between January 2013 and January 2024, we enrolled 221 eligible patients with unprotected left main coronary artery disease treated by PCI; among these, 13.1% were treated by OCT-guided PCI and 86.9% by angiographic-guided PCI. At a median follow up of 30.16 months (interquartile range: 14.3–60 months), Kaplan–Meier survival analysis revealed a significantly higher survival probability in the OCT group compared to the non-OCT group (log-rank p = 0.034), with no significant differences between the groups regarding procedural success rate. In the multivariable Cox proportional hazards model, adjusting for other relevant covariates, OCT was borderline non-significantly independently associated with a 63% reduction in mortality (HR = 0.37, p = 0.063). Conclusions: In our study, OCT-guided PCI was associated with early procedural distinctions and a trend toward improved unadjusted survival in LM PCI. The findings highlight the potential procedural advantages of OCT, as well as the need for larger prospective studies to establish its long-term clinical benefits in left main interventions. Full article
(This article belongs to the Section Cardiovascular Medicine)
Show Figures

Figure 1

15 pages, 925 KiB  
Article
Are There Gender Differences in the Benefits of Multidisciplinary Care in Patients with Heart Failure? Results from the UMIPIC Program
by Alicia Conde-Martel, Manuel Méndez-Bailón, Manuel Montero-Pérez-Barquero, Álvaro González-Franco, José Manuel Cerqueiro, José Pérez-Silvestre, José María Fernández-Rodríguez, Pau Llàcer, Jesús Casado, Francesc Formiga, Prado Salamanca-Bautista, Jose Carlos Arévalo-Lorido and Luis Manzano
J. Clin. Med. 2025, 14(16), 5818; https://doi.org/10.3390/jcm14165818 - 17 Aug 2025
Viewed by 202
Abstract
Background/Objectives: Heart failure (HF) is a leading cause of hospitalization in older adults, with significant sex differences in presentation, treatment, and outcomes. Transitional care models may benefit women more, yet they often receive less follow-up. This study assessed whether the clinical impact [...] Read more.
Background/Objectives: Heart failure (HF) is a leading cause of hospitalization in older adults, with significant sex differences in presentation, treatment, and outcomes. Transitional care models may benefit women more, yet they often receive less follow-up. This study assessed whether the clinical impact of the UMIPIC multidisciplinary HF management program differs by sex. Methods: This prospective, multicenter, observational cohort study included HF patients enrolled in the UMIPIC program or followed through conventional care in the RICA registry. Outcomes (30-day and one-year mortality and readmissions) were compared between groups, stratified by sex. Multivariate Cox models adjusted for age, HF phenotype, comorbidities, and baseline therapy. Results: A total of 5644 HF patients were included, with 2034 (36%) managed in UMIPIC and 3610 (64%) receiving conventional care. Women represented 55% of UMIPIC patients and were older, with higher prevalence of hypertension, anemia, and HF with preserved ejection fraction (HFpEF) compared to conventional care. At 30 days, women in UMIPIC had lower all-cause mortality (4.0% vs. 8.0%), cardiovascular mortality (2.0% vs. 6.0%), and readmissions (9.0% vs. 18.0%; all p < 0.01); these benefits persisted at one year. In multivariate analysis, UMIPIC enrollment remained protective (HR: 0.79; 95% CI: 0.71–0.87; p < 0.001). In men, UMIPIC patients were older with more comorbidities and higher HFpEF prevalence. They also showed lower 30-day mortality (2.0% vs. 8.0%; p < 0.05) and readmissions (8.0% vs. 18.0%; p < 0.01), with benefits maintained at one year. UMIPIC enrollment remained independently associated with reduced one-year mortality in men (HR: 0.79; 95% CI: 0.71–0.88; p < 0.001). Conclusions: The UMIPIC multidisciplinary care model reduced one-year mortality and readmissions in both women and men with HF, supporting integrated care strategies to improve outcomes in this high-risk population. Full article
(This article belongs to the Section Cardiovascular Medicine)
Show Figures

Figure 1

14 pages, 711 KiB  
Systematic Review
Clinical Characteristics and Outcomes of SMARCA4-Mutated or Deficient Malignancies: A Systematic Review of Case Reports and Series
by Ryuichi Ohta, Natsumi Yamamoto, Kaoru Tanaka, Chiaki Sano and Hidetoshi Hayashi
Cancers 2025, 17(16), 2675; https://doi.org/10.3390/cancers17162675 - 16 Aug 2025
Viewed by 277
Abstract
Background/Objectives: SMARCA4-deficient or SMARCA4-mutated cancers are rare but highly aggressive tumors with poor differentiation, resistance to conventional treatments, and limited clinical guidance. While thoracic SMARCA4-deficient undifferentiated tumors are relatively well described, the full spectrum of SMARCA4-altered cancers across different organs and their therapeutic [...] Read more.
Background/Objectives: SMARCA4-deficient or SMARCA4-mutated cancers are rare but highly aggressive tumors with poor differentiation, resistance to conventional treatments, and limited clinical guidance. While thoracic SMARCA4-deficient undifferentiated tumors are relatively well described, the full spectrum of SMARCA4-altered cancers across different organs and their therapeutic responses remains poorly understood. This study aimed to systematically review published case reports and case series to clarify the clinical characteristics, molecular features, treatment patterns, and survival outcomes of SMARCA4-altered malignancies. Methods: We conducted a systematic review of case reports and case series published between 2015 and 2025 using PubMed, Embase, and Web of Science. Eligible studies included adult patients with immunohistochemically or genetically confirmed SMARCA4-deficient or SMARCA4-mutated tumors. Key clinical, pathological, molecular, therapeutic, and outcome-related data were extracted. Descriptive statistics were used, and exploratory subgroup analyses were performed based on tumor type and treatment modality. The review protocol was registered in PROSPERO (CRD420251088805). Results: A total of 109 studies reporting 160 individual patients were included. Most tumors arose in the thorax (40.0%), followed by gastrointestinal (17.5%) and gynecologic sites (15.6%). The median age was 58 years, with a male predominance (70.0%) and frequent smoking history (44.4%). Platinum-based chemotherapy was administered in 62.5% of cases, and immune checkpoint inhibitors (ICIs) were used in 25.6%. Among ICI-treated patients, partial responses or stable disease were observed in 80.5%. The median progression-free survival (PFS) was 4.0 months, and the median overall survival (OS) was 5.0 months. Conclusions: SMARCA4-altered cancers are clinically and molecularly diverse but uniformly aggressive, with limited therapeutic benefit from conventional chemotherapy. Immune checkpoint inhibitors may offer improved outcomes in select patients, particularly those with thoracic tumors. Early molecular profiling, rare tumor registries, and biomarker-driven trials are crucial for guiding future treatment strategies. Full article
(This article belongs to the Section Clinical Research of Cancer)
Show Figures

Figure 1

17 pages, 258 KiB  
Article
Survival Patterns and Mortality Causes in Patients with Invasive Ependymoma: A Retrospective Cohort Analysis from 2000 to 2019
by Anas Elgenidy, Khaled Saad, Amir Aboelgheet, Eman F. Gad, Usama El-Shokhaiby, Thamer A. M. Alruwaili, Abdelrahman N. Abdelal, Kawashty R. Mohamed, Mohammad Bazzazeh, Mohamed Hesn, Abdelrahman H. Elshimy, Aya Sayed, Sara Magdy, Doaa Ali Gamal, Amira A. Elhoufey, Shymaa Adel Ismael, Ahmed M. Afifi, Mohamed Fahmy M. Ibrahim and Amany Ragab
Med. Sci. 2025, 13(3), 139; https://doi.org/10.3390/medsci13030139 - 16 Aug 2025
Viewed by 189
Abstract
Background: Ependymomas are primary CNS neoplasms that arise from the ependymal cells of the brain and spinal cord, accounting for 3–6% of all CNS tumors. Aims: This study provides a comprehensive analysis of ependymoma survival patterns and examines non-cancer causes of death in [...] Read more.
Background: Ependymomas are primary CNS neoplasms that arise from the ependymal cells of the brain and spinal cord, accounting for 3–6% of all CNS tumors. Aims: This study provides a comprehensive analysis of ependymoma survival patterns and examines non-cancer causes of death in the US. Methods: This retrospective study used data from SEER 17 registries between 2000 and 2019 to evaluate the incidence of ependymoma, as well as the survival and mortality trends in the US. Results: A total of 3821 patients were included, with 842 (22%) deaths. The highest mortality was observed in younger patients (<18 years) within one year of diagnosis (SMR, 54.77; 95% CI, 38.95–74.88). Brain and other nervous system cancers were the leading causes of death, followed by non-cancer causes, particularly cerebrovascular diseases, pneumonia, influenza, and septicemia. The survival rates observed at one, three, and five years were 94% (95% CI: 0.94–0.95), 88% (95% CI: 0.87–0.89), and 84% (95% CI: 0.82–0.85), respectively. Conditional survival improved over time, with a three-year conditional relative survival rate of 92% after one year of diagnosis and 96% for those who survived five years. Conclusion: The death rate was highest among pediatric patients under 18 years of age. Cerebrovascular disorders were the leading non-cancer cause of death across all time intervals. The probability of surviving for three years increases for patients who have already survived one, three, or five years post-diagnosis. Full article
(This article belongs to the Section Cancer and Cancer-Related Research)
14 pages, 2222 KiB  
Article
BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome
by Sourat Darabi, Phillip Stafford, David R. Braxton, Carlos E. Zuazo, Taylor J. Brodie and Michael J. Demeure
Int. J. Mol. Sci. 2025, 26(16), 7910; https://doi.org/10.3390/ijms26167910 - 16 Aug 2025
Viewed by 215
Abstract
BRAF inhibitors have a 50–70% response rate in melanoma but are less effective for thyroid cancer. Differential response may be from activation or expression of downstream mitogen-activated protein kinase (MAPK) pathway genes. Retrospective analysis compared whole exome and transcriptome sequencing in melanoma and [...] Read more.
BRAF inhibitors have a 50–70% response rate in melanoma but are less effective for thyroid cancer. Differential response may be from activation or expression of downstream mitogen-activated protein kinase (MAPK) pathway genes. Retrospective analysis compared whole exome and transcriptome sequencing in melanoma and thyroid cancers from April 2019 to October 2023. The MAPK Activation Score (MPAS) was calculated using Z-score normalized/log-transformed values indicating expression across 10 MAPK-associated genes. Our tumor registry provided outcome data. BRAF V600E mutations were identified in 33 of 200 (17%) melanomas and 14 (7%) had other BRAF mutations (V600K/R). Of 49 thyroid tumor samples, BRAF V600E mutations were found in 19 (39%). RNA expression of BRAF and the 10 MAPK-associated genes were increased in melanomas with V600E compared to wild-type BRAF (p = 0.02). Conversely, BRAF V600E mutation in thyroid cancer was not associated with increased expression nor MAPK pathway activation. No significant difference in overall survival based on BRAF mutation was observed in the subset of patients where data was available. The MAPK pathway is differentially affected by the different cancers, with increased MAPK activation observed in melanoma and not in thyroid cancer. This may account in part for the observed differential response to BRAF inhibitors. Full article
Show Figures

Figure 1

14 pages, 1413 KiB  
Article
Beyond the Growth: A Registry-Based Analysis of Global Imbalances in Artificial Intelligence Clinical Trials
by Chan-Young Kwon
Healthcare 2025, 13(16), 2018; https://doi.org/10.3390/healthcare13162018 - 16 Aug 2025
Viewed by 173
Abstract
Background/Objectives: While the integration of artificial intelligence (AI) into clinical research is rapidly accelerating, a comprehensive analysis of the global AI clinical trial landscape has been limited. This study presents the first systematic characterization of AI-related clinical trials registered in the World [...] Read more.
Background/Objectives: While the integration of artificial intelligence (AI) into clinical research is rapidly accelerating, a comprehensive analysis of the global AI clinical trial landscape has been limited. This study presents the first systematic characterization of AI-related clinical trials registered in the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). It aims to map global trends, identify patterns of concentration, and analyze the structure of international collaboration. Methods: A search of the WHO ICTRP was conducted on 20 June 2025. Following a two-stage screening process, the dataset was analyzed for temporal trends, geographic distribution, disease and technology categories, and international collaboration patterns using descriptive statistics and network analysis. Results: We identified 596 AI clinical trials across 62 countries, with registrations growing exponentially since 2020. The landscape is defined by extreme geographic concentration, with China accounting for the largest share of trial participations (35.6%), followed by the USA (8.5%). Research is thematically concentrated in Gastroenterology (22.8%) and Oncology (20.1%), with Diagnostic Support (45.6%) being the most common technology application. Formal international collaboration is critically low, with only 8.7% of trials involving multiple countries, revealing a fragmented collaboration landscape. Conclusions: The global AI clinical trial landscape is characterized by rapid but deeply imbalanced growth. This concentration and minimal international collaboration undermine global health equity and the generalizability of AI technologies. Our findings underscore the urgent need for a fundamental shift toward more inclusive, transparent, and collaborative research models to ensure the benefits of AI are realized equitably for all of humanity. Full article
(This article belongs to the Special Issue Artificial Intelligence in Healthcare: Opportunities and Challenges)
Show Figures

Figure 1

13 pages, 1865 KiB  
Systematic Review
High Outcome-Reporting Bias in Randomized-Controlled Trials of Acupuncture for Cancer Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Epidemiological Study
by Rachele Penati, Riccardo Vecchio, Roberto Gatto, Anna Odone and Silvia Deandrea
Curr. Oncol. 2025, 32(8), 462; https://doi.org/10.3390/curroncol32080462 - 15 Aug 2025
Viewed by 239
Abstract
Selective outcome-reporting bias refers to the selective reporting of a subset of study findings. This methodological limitation may occur in cancer-related acupuncture studies, where valid empirical studies on psychometric performance are still lacking. We assessed the risk of selective outcome reporting bias in [...] Read more.
Selective outcome-reporting bias refers to the selective reporting of a subset of study findings. This methodological limitation may occur in cancer-related acupuncture studies, where valid empirical studies on psychometric performance are still lacking. We assessed the risk of selective outcome reporting bias in studies published in English that were included in a systematic review on acupuncture for preventing cancer chemotherapy-induced nausea and vomiting. For each study, we searched for registry availability and, if present, assessed its validity. We described each study outcome (nausea, vomiting, or both) according to the following seven items: type of outcome, domain, specific measurement, specific metric, type of data, methods of aggregation, and timepoint unit and time. Eleven studies published between 1987 and 2019 in English were evaluated. Only four (36%) had a registry, of which only two were prospective and therefore considered valid. Discrepancies were found in the specific measurement of the outcome in two studies and in the specific metric. In many other cases, discrepancies were not evaluable due to missing information. No study reported complete outcomes as planned in the published protocol. Communication about the importance of prospective trial registration, including outcome details, should be enforced to reduce the risk of selective outcome reporting bias in oncology acupuncture studies. Full article
Show Figures

Figure 1

13 pages, 3885 KiB  
Article
Clinical Effectiveness and Safety of Reduced-Dose Prasugrel in Asian Patients: The PROMISE-TW Registry
by Yu-Chen Wang, Chiung-Ray Lu, Yi-Tzone Shiao, Kuan-Cheng Chang, Chun-Hung Su, Yu-Wei Chiu, Chien-Lung Huang, Wei-Shin Liu, Ching-Lung Yu, Ming-Jer Hsieh, Ye-Hsu Lu, Ho-Ming Su, Po-Chih Lin, Hsin-Bang Leu and Wen-Lieng Lee
J. Clin. Med. 2025, 14(16), 5791; https://doi.org/10.3390/jcm14165791 - 15 Aug 2025
Viewed by 211
Abstract
Background: Reduced-dose prasugrel is widely used in East Asia for acute coronary syndrome (ACS), but real-world data in diverse Asian populations are limited. This study evaluated its effectiveness and safety in Taiwanese patients. Methods: The PROMISE-TW Registry was a multicenter, retrospective study including [...] Read more.
Background: Reduced-dose prasugrel is widely used in East Asia for acute coronary syndrome (ACS), but real-world data in diverse Asian populations are limited. This study evaluated its effectiveness and safety in Taiwanese patients. Methods: The PROMISE-TW Registry was a multicenter, retrospective study including 1167 patients with ACS or chronic coronary syndrome (CCS) treated with reduced-dose prasugrel (20 mg loading, 3.75 mg maintenance) across 13 hospitals in Taiwan from 2018 to 2022. The primary endpoint was 1-year major adverse cardiovascular events (MACEs: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke). Secondary outcomes included composite ischemic events and major bleeding (BARC 3–5). Results: Among enrolled patients (mean age 63.9 years; 81.2% male; 83% ACS), percutaneous coronary intervention was performed in 90.8%. At one year, MACEs occurred in 1.9%, composite ischemic events in 8.2%, and major bleeding in 0.8%. Subgroup analysis identified prior stroke, diabetes, and chronic total occlusion intervention as predictors of bleeding. Male sex, chronic kidney disease, and left circumflex artery intervention predicted higher ischemic risk. Conclusions:Reduced-dose prasugrel provided effective ischemic protection and low bleeding rates in Taiwanese patients, especially those with ACS. These findings support the clinical utility of dose-adjusted prasugrel in East Asian populations and highlight the importance of individualized risk assessment. Full article
(This article belongs to the Section Cardiovascular Medicine)
Show Figures

Figure 1

Back to TopTop